83602-41-9

Basic information

• Product Name: SDZ 33-243
• Synonyms: SDZ 33-243;(3R,4R)-3-Acetoxy-N-methyl-5-[(E)-1-propenyl]-cyclo(L-Leu-L-Abu-Sar-N-methyl-L-Leu-L-Val-N-methyl-L-Leu-L-Ala-D-Ala-N-methyl-L-Leu-N-methyl-L-Leu-N-methyl-L-Val-);(3R,4R)-3-Acetoxy-N-methyl-5-[(E)-1-propenyl]cyclo(L-Leu-L-Abu-Sar-N-methyl-L-Leu-L-Val-N-methyl-L-Leu-L-Ala-D-Ala-N-methyl-L-Leu-N-methyl-L-Leu-N-methyl-L-Val-);(3R,4R)-N-Methyl-3-acetoxy-5-[(E)-1-propenyl]-cyclo(L-Leu-L-Abu-Sar-N-methyl-L-Leu-L-Val-N-methyl-L-Leu-L-Ala-D-Ala-N-methyl-L-Leu-N-methyl-L-Leu-N-methyl-L-Val-);B-3-243;Cyclosporine A acetate;Cyclosporin A Acetate;Aids097134
• CAS NO: 83602-41-9
• Molecular Formula: C₆₄H₁₁₃N₁₁O₁₃
• Molecular Weight: 1244.66
• Product Categories: Intermediates & Fine Chemicals;Peptides;Pharmaceuticals
• Mol File: 83602-41-9.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 1283.7°C at 760 mmHg
• Flash Point: 730.2°C
• Appearance: /
• Density: 1.015g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: SDZ 33-243(CAS DataBase Reference)
• NIST Chemistry Reference: SDZ 33-243(83602-41-9)
• EPA Substance Registry System: SDZ 33-243(83602-41-9)

Safety Data

• Hazardous Substances Data: 83602-41-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 83602-41-9 differently. You can refer to the following data:
1. A non-immunosuppressive analog
2. A non-immunosuppressive analog of Cyclosporin A.

InChI:InChI=1/C64H113N11O13/c1-26-28-29-41(15)53(88-44(18)76)52-57(81)67-45(27-2)59(83)70(20)34-49(77)71(21)47(31-36(5)6)56(80)69-50(39(11)12)61(85)72(22)48(32-37(7)8)55(79)65-42(16)54(78)66-43(17)58(82)75(25)64(19,33-38(9)10)63(87)68-46(30-35(3)4)60(84)73(23)51(40(13)14)62(86)74(52)24/h26,28,35-43,45-48,50-53H,27,29-34H2,1-25H3,(H,65,79)(H,66,78)(H,67,81)(H,68,87)(H,69,80)/b28-26+/t41-,42+,43-,45+,46+,47+,48+,50+,51+,52+,53-,64+/m1/s1

Upstream product

• 59865-13-3 cyclosporin A 
• 108-24-7 acetic anhydride 
• 59865-13-3 cyclosporine A 
• 83563-94-4 C₆₄H₁₁₃N₁₁O₁₃ 
• 121584-52-9 C₆₂H₁₀₉N₁₁O₁₄ 
• 1754-88-7 ethylenetriphenylphosphorane 

Downstream Products

• 59865-15-5 C₆₂H₁₁₃N₁₁O₁₂ 
• 121584-08-5 C₆₉H₁₁₅N₁₁O₁₃ 
• 59865-13-3 C₆₂H₁₁₁N₁₁O₁₂ 
• 83563-94-4 C₆₄H₁₁₃N₁₁O₁₃ 
• 111722-68-0 C₆₇H₁₁₃N₁₁O₁₂ 
• 111722-68-0 C₆₇H₁₁₃N₁₁O₁₂ 
• 121886-75-7 [(3R,4R)-3-hydroxy-4-methyl-6-(2-hydroxyethyl)-N-MeNle]-1-cyclosporin 
• 286852-20-8 MeLeuValMeLeuAlaDAlaMeLeuMeLeuMeValMeBmt(OAc)AbuSar-Ome 
• 159391-85-2 Acetylcyclosporin 4,7-bis(benzyl thioamidate) 
• 121584-52-9 [(3R,4R)-3-acetyloxy-4-methyl-6-oxo-N-MeNle]-1-cyclosporin 
• 89270-28-0 AM1 
• 138957-23-0 η-acetoxyacetylcyclosporin A 

Relevant articles and documents

Synthesis of [ω-3H-MeBmt1]-cyclosporin A

[3H]-Cyclosporin A labeled at the first amino acid ([ω-3H-MeBmt1]CS) has been prepared by tritium gas hydrogenolysis of [O-acetyl-ω-bromo- MeBmt1]CS followed by deprotection with methanolic sodium methoxide. The requisite bromo intermediate was prepared by bromination of [O-acetyl- MeBmt1]CS with N-bromosuccinimide. After synthesis and purification, 2.45 m8 of [ω-3H-MeBmt1]CS with a total activity of 327 MBq were produced with a radiochemical purity >97%, and specific activity of 160 GBq/mmol (4.3 Ci/mmol).

Development of a practical process for the opening of macrocyclic Cyclosporin a and amino acid deletion

A practical and robust process for the derivatization of Cyclosporin A was demonstrated. The processes rely on the opening of Cyclosporin A and removal of amino acid fragments via Edman degradation, with the isolation of crystalline tetrafluoroboric salts of the corresponding acyclic polypeptides.

Targeting Extracellular Cyclophilin A via an Albumin-Binding Cyclosporine A Analogue

An albumin-binding CsA analogue 4MCsA was achieved by attachment of a thiol-reactive maleimide group at the side-chain of P4 position of CsA derivative. 4MCsA was semi-synthesized from CsA, and the cell-impermeability of albumin-4MCsA was detected by mass spectrometry and a competitive flow cytometry. 4MCsA exhibits inhibition of chemotaxis activity and inflammation by targeting extracellular CypA without immunosuppressive effect and cellular toxicity. These combined results suggested that 4MCsA can be restricted extracellularly through covalently binding to Cys34 of albumin with its maleimide group, and regulate the functions of cyclophilin A extracellularly.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

Cyclosporin derivatives for the treatment and prevention of a viral infection

The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.